Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-001 in moderate to severe ulcerative colitis
2025-524719-35-00Phase 2Authorised
- Sponsor
- Mage Biologics Inc.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing MB-001 with Placebo (2 arms). Primary endpoints: Incidence of adverse events, Change in clinical laboratory parameters, physical examination findings, and vital signs and 1 more. Planned start Apr 2026; status: authorised.
02
Drugs
MB-001
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2025-524719-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524719-35-00.